Elimination of Antibodies to Recombinant Enzyme in Pompe's Disease
Authors:
- Nancy J. MendelsohnNMNancy J. Mendelsohn
- Yoav H. MessingerYMYoav H. Messinger
- Amy S. RosenbergARAmy S. Rosenberg
- Priya S. KishnaniPKPriya S. Kishnani
- 8 January 2009
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 360 (2) , 194-195
Abstract
Infantile Pompe's disease is due to a deficiency of lysosomal acid alpha glucosidase (GAA). In patients in whom GAA is not produced, a status called cross-reacting immunologic material (CRIM)–negative, enzyme-replacement therapy with recombinant human GAA (rhGAA) has uniformly led to high titers of anti-rhGAA antibody, with an ultimately fatal outcome.1 Previous attempts at eliminating rhGAA antibodies in these patients have failed.1-3 We report the successful induction of immune modulation in a CRIM-negative patient with Pompe's disease who continues to be antibody-free at 24 months of age and continues to gain motor milestones.Keywords
This publication has 4 references indexed in Scilit:
- Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease modelClinical and Experimental Immunology, 2008
- Recombinant human acid α-glucosidaseNeurology, 2007
- Nephrotic Syndrome Complicating α-Glucosidase Replacement Therapy for Pompe DiseasePediatrics, 2004
- Recombinant human acid ??-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trialGenetics in Medicine, 2001